奥沙利铂联合卡培他滨新辅助化疗在局部进展期低位直肠癌中的应用效果  

Application effect of oxaliplatin combined with capecitabine neoadjuvant chemotherapy in locally advanced low rectal cancer

作　　者：李守帅[1] 田立民[1] 庄坤[2] 刘家铭 LI Shoushuai;TIAN Limin;ZHUANG Kun;LIU Jiaming(Third Department of General Surgery,Xi'an Central Hospital,Xi’an 710004,Shaanxi,China;Department of Gastroenterology,Xi'an Central Hospital,Xi’an 710004,Shaanxi,China)

机构地区：[1]西安市中心医院普外三科,西安710004 [2]西安市中心医院消化内科,西安710004

出　　处：《癌症进展》2023年第6期663-666,共4页Oncology Progress

摘　　要：目的探讨奥沙利铂联合卡培他滨新辅助化疗在局部进展期低位直肠癌中的应用效果。方法将80例局部进展期低位直肠癌患者按化疗方案的不同分为对照组与观察组,每组40例。对照组患者接受奥沙利铂+亚叶酸钙+5-氟尿嘧啶(FOLFOX6)方案新辅助化疗,观察组患者接受奥沙利铂+卡培他滨(XELOX)方案新辅助化疗。比较两组患者预后情况、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)]水平、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+))、不良反应发生情况。结果随访1年,观察组患者临床转移率低于对照组,总生存率高于对照组,差异均有统计学意义(P﹤0.05)。化疗后,两组患者CEA、CA125、CA19-9水平均明显降低,且观察组患者CEA、CA125、CA19-9水平均明显低于对照组,差异均有统计学意义(P﹤0.01)。化疗后,两组患者CD3^(+)、CD4^(+)水平均明显升高,CD8^(+)水平均明显降低,且观察组患者CD3^(+)、CD4^(+)水平均明显高于对照组,CD8^(+)水平明显低于对照组,差异均有统计学意义(P﹤0.01)。观察组患者不良反应总发生率低于对照组,差异有统计学意义(P﹤0.05)。结论奥沙利铂联合卡培他滨新辅助治疗局部进展期低位直肠癌,可有效增强患者的免疫力,消除肿瘤细胞,同时还能降低不良反应发生率,安全性较高,有助于改善预后。Objective To investigate the application effect of oxaliplatin combined with capecitabine neoadjuvant chemotherapy in locally advanced low rectal cancer.Method A total of 80 patients with locally advanced low rectal cancer were divided into control group and observation group according to different chemotherapy regimens with 40 cases in each group.The control group received oxaliplatin^(+)leucovorin^(+)5-fluorouracil(FOLFOX6)regimen neoadjuvant chemotherapy,and the observation group received oxaliplatin^(+)capecitabine(XELOX)regimen neoadjuvant chemotherapy.The prognosis,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 19-9(CA19-9)]levels,immune function indexes(CD3^(+),CD4^(+),CD8^(+)),and adverse reactions were compared between the two groups.Result Followed-up for 1 year,the clinical metastasis rate of the observation group was lower than that of the control group,and the overall survival rate was higher than that of the control group,and the differences were statistically significant(P<0.05).After the chemotherapy,the levels of CEA,CA125,and CA19-9 in the two groups were significantly decreased,and the levels of the above indicators in the observation group were significantly lower than those in the control group,and the differences were statistically significant(P<0.01).After the chemotherapy,the levels of CD3^(+)and CD4^(+)in the two groups were significantly increased,and the levels of CD8^(+)were significantly decreased,moreover,the levels of CD3^(+)and CD4^(+)in the observation group were significantly higher than those in the control group,and the level of CD8^(+)in the observation group was significantly lower than that in the control group,and the differences were statistically significant(P<0.01).The total incidence of adverse events in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Oxaliplatin combined with capecitabine in the neoadjuvant treatment of locally adva

关 键 词：奥沙利铂 卡培他滨 新辅助化疗 局部进展期 低位直肠癌 

分 类 号：R735.37[医药卫生—肿瘤]